Successful treatment of recurrent focal segmental glomerulosclerosis after renal transplantation by lymphocytapheresis and rituximab

Transplant International

Volumn 23, Issue 9, 2010, Pages

  Shimizu, Masaki ^a   Kitagawa, Kiyoki ^a   Nishio, Sayaka ^a   Yokoyama, Tadafumi ^a   Furuichi, Kengo ^b   Ohta, Kazuhide ^c   Wada, Takashi ^a   Yachie, Akihiro ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION KANAZAWA MEDICAL CENTER   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLPREDNISOLONE; RITUXIMAB;

ADULT; APHERESIS; CASE REPORT; CLINICAL FEATURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOCAL GLOMERULOSCLEROSIS; HUMAN; KIDNEY TRANSPLANTATION; LETTER; LYMPHOCYTAPHERESIS; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEINURIA; RECURRENT DISEASE; SYMPTOM; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIGENS, CD20; BIOPSY; DIAGNOSIS, DIFFERENTIAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; GRAFT REJECTION; HUMANS; IMMUNOLOGIC FACTORS; INJECTIONS, INTRAVENOUS; KIDNEY; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; LEUKAPHERESIS; MICROSCOPY, ELECTRON; RECURRENCE; REMISSION INDUCTION; YOUNG ADULT;

EID: 77955256614     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2010.01118.x     Document Type: Letter

References (12)

1. Tejani A, Stablein DH. Recurrence of focal segmental glomerulosclerosis posttransplantation: a special report of the North American Pediatric Renal Transplant Cooperative Study. J Am Soc Nephrol 1992 12 (Suppl. S258.
2. Fine RN. Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol 2007 22 : 496.
3. Koyama A, Fujisaki M, Kobayashi M, et al. A glomerular permeability factor produced by human T cell hybridomas. Kidney Int 1991 40 : 453.
4. Savin VJ, Sharma R, Sharma M, et al. Circulating factor associated with increased glomerular permeability to albumin in recurrent focal segmental glomerulosclerosis. N Engl J Med 1996 334 : 878.
5. Yokoyama H, Wada T, Zhang W, et al. Advances in apheresis therapy for glomerular diseases. Clin Exp Nephrol 2007 11 : 122.
6. Haffner D, Fischer DC. Nephrotic syndrome and rituximab: facts and perspectives. Pediatr Nephrol 2009 24 : 1433.
7. Bosch T. Therapeutic apheresis - state of the art in the year 2005. Ther Apher Dial 2005 9 : 459.
8. Yokoyama H, Shimizu M, Wada T, et al. The beneficial effects of lymphocytapheresis for treatment of nephrotic syndrome. Ther Apher 2002 6 : 167.
9. Hristea D, Hadaya K, Maragon N, et al. Successful treatment of recurrent focal segmental glomerulosclerosis after kidney transplantation by plasmapheresis and rituximab. Transpl Int 2007 20 : 102.
10. Meyer TN, Thaiss F, Stahl RAK. Immunoadsorbtion and rituximab therapy in a second living-related kidney transplant patient with recurrent focal segmental glomerulosclerosis. Transpl Int 2007 20 : 1066.
11. Nozu K, Iijima K, Fujisawa M, et al. Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephritic syndrome. Pediatr Nephrol 2005 20 : 1660.
12. Jordan SC, Glotz D. Is rituximab safe to use in kidney transplant patients? Am J Transplant 2010 10 : 8.